Geissler K, Friedl J, Hauser I
Abteilung für Hämatologie und Hämostaseologie, Klinik für Innere Medizin I, AKH Wien.
Wien Klin Wochenschr. 1994;106(10):309-14.
Hodgkin's disease has become the prototype of a curable neoplastic condition. In localized disease (stages I and II) cure can be achieved with radiotherapy alone unless B-symptoms are present. In case of B-symptoms or generalized disease (stages III and IV) the administration of polychemotherapy is mandatory. In advanced stages combinations of the non-cross-resistant regimens MOPP and ABVD seem to be the most effective. In patients relapsing from the MOPP/ABVD or MOPP/ABV regimen salvage chemotherapy offers a chance of remission but not cure. Such patients, in particular those with a short first remission, are candidates for autologous stem cell transplantation which can still induce durable remissions in a subset of patients. Considering the long term complications such as infertility and the development of secondary neoplasms one has to carefully balance the benefits against the potential risks of the initial treatment approach.
霍奇金淋巴瘤已成为可治愈的肿瘤疾病的典范。在局限性疾病（I期和II期）中，除非存在B症状，否则仅通过放疗即可实现治愈。对于出现B症状或全身性疾病（III期和IV期）的情况，必须进行多药化疗。在晚期，非交叉耐药方案MOPP和ABVD的联合使用似乎最为有效。对于从MOPP/ABVD或MOPP/ABV方案复发的患者，挽救性化疗提供了缓解的机会，但无法治愈。此类患者，尤其是首次缓解期较短的患者，是自体干细胞移植的候选者，自体干细胞移植仍可使一部分患者诱导出持久缓解。考虑到诸如不育和继发性肿瘤发生等长期并发症，必须仔细权衡初始治疗方法的益处与潜在风险。
